STRAINS, COMPOSITIONS AND METHODS OF USE
The present invention relates to a composition comprising Lactobacillus crispatus LB714R, deposited under the accession number DSM 33732, Lactobacillus gasseri LB905R deposited under accession number DSM 34094, Lactobacillus crispatus LB912R deposited under accession number DSM 34095, Lactobacillus jensenii LB918R deposited under accession number DSM 34096, or Lactobacillus crispatus LB919R deposited under accession number DSM 34097.
1 .- 12 . (canceled)
13 . A composition comprising an isolated bacterial strain capable of prevention, inhibition, or treatment of biofilm formation of pathogens, wherein the bacterial strain is selected from Lactobacillus crispatus LB714R, deposited under the accession number DSM 33732, Lactobacillus crispatus LB919R deposited under accession number DSM 34097 , Lactobacillus jensenii LB918R deposited under accession number DSM 34096, Lactobacillus crispatus LB912R deposited under accession number DSM 34095, or Lactobacillus gasseri LB905R deposited under accession number DSM 34094, wherein the isolated bacterial strain is stabilized in freeze dried, lyophilized or microencapsulated forms or wherein the non-viable cells is provided as a lysate, as a fraction, as a ferment, as metabolites, as an extract, as a derivative, as analogues, as postbiotics, as paraprobiotics or as a mutant of one of the bacterial strains.
14 . A vaginal microbiome transplant comprising an isolated bacterial strain capable of prevention, inhibition, or treatment of biofilm formation of pathogens, wherein the bacterial strain is selected from Lactobacillus crispatus , in particular comprising Lactobacillus crispatus LB714R, deposited under the accession number DSM 33732, Lactobacillus crispatus LB919R deposited under accession number DSM 34097 , Lactobacillus jensenii LB918R deposited under accession number DSM 34096, Lactobacillus crispatus LB912R deposited under accession number DSM 34095, or Lactobacillus gasseri LB905R deposited under accession number DSM 34094, wherein the isolated bacterial strain is stabilized in freeze dried, lyophilized or microencapsulated forms or wherein the non-viable cells is provided as a lysate, as a fraction, as a ferment, as metabolites, as an extract, as a derivative, as analogues, as postbiotics, as paraprobiotics or as a mutant of one of the bacterial strains.
15 . The vaginal microbiome transplant according to claim 14 , wherein the vaginal microbiome transplant further comprises a lactic acid bacterial strain selected from one or more Pediococcus strains (such as Pediococcus pentosaceus LB606R, deposited under the deposit accession number DSM 33730); and/or the one or more Lactiplantibacillus strains, (such as Lactiplantibacillus plantarum LB679R, deposited under the deposit accession number DSM 33731).
16 . The vaginal microbiome transplant according to claim 14 , wherein the vaginal microbiome transplant is formulated as a suspension, spray, gel, cream, lotion, powder, capsule, oil, solution for lavages, ovules, a vaginal insert, a suppository, lozenge, tablets, microencapsulated product or in form of a food supplement or a food product.
17 . An isolated bacterial strain capable of prevention, inhibition, or treatment of biofilm formation of pathogens, wherein the bacterial strain is selected from Lactobacillus crispatus , in particular comprising Lactobacillus crispatus LB714R, deposited under the accession number DSM 33732, Lactobacillus crispatus LB919R deposited under accession number DSM 34097, Lactobacillus jensenii LB918R deposited under accession number DSM 34096, Lactobacillus crispatus LB912R deposited under accession number DSM 34095, or Lactobacillus gasseri LB905R deposited under accession number DSM 34094, wherein the isolated bacterial strain is stabilized in freeze dried, lyophilized or microencapsulated forms or wherein the non-viable cells is provided as a lysate, as a fraction, as a ferment, as metabolites, as an extract, as a derivative, as analogues, as postbiotics, as paraprobiotics or as a mutant of one of the bacterial strains.
18 . A medical composition comprising one or more bacterial strains capable of prevention, inhibition, or treatment of biofilm formation of pathogens, wherein the bacterial strain is selected from the species Lactobacillus crispatus, Lactobacillus gasseri or, Lactobacillus jensenii , wherein the isolated bacterial strain is stabilized in freeze dried, lyophilized or microencapsulated forms or wherein the non-viable cells is provided as a lysate, as a fraction, as a ferment, as metabolites, as an extract, as a derivative, as analogues, as postbiotics, as paraprobiotics or as a mutant of one of the bacterial strains.
19 . A composition comprising a bacterial strain capable of prevention, inhibition, or treatment of biofilm formation of pathogens, wherein the bacterial strain is selected from one or more Lactobacillus crispatus , one or more Lactobacillus gasseri , or one or more Lactobacillus jensenii for the prevention and/or treatment of a vaginal infection in a human or in an animal, wherein the isolated bacterial strain is stabilized in freeze dried, lyophilized or microencapsulated forms or wherein the non-viable cells is provided as a lysate, as a fraction, as a ferment, as metabolites, as an extract, as a derivative, as analogues, as postbiotics, as paraprobiotics or as a mutant of one of the bacterial strains.
20 . A composition comprising a bacterial strain capable of prevention, inhibition, or treatment of biofilm formation of pathogens, wherein the bacterial strain is selected from one or more Lactobacillus crispatus , one or more Lactobacillus gasseri , or one or more Lactobacillus jensenii for the improvement of fertility of a human or an animal and/or reducing the risk of premature birth of a human or an animal, wherein the isolated bacterial strain is stabilized in freeze dried, lyophilized or microencapsulated forms or wherein the non-viable cells is provided as a lysate, as a fraction, as a ferment, as metabolites, as an extract, as a derivative, as analogues, as postbiotics, as paraprobiotics or as a mutant of one of the bacterial strains.
21 . A composition comprising a bacterial strain selected from one or more Lactobacillus crispatus , one or more Lactobacillus gasseri , or one or more Lactobacillus jensenii for the prevention, inhibition, or treatment of biofilm formation, wherein the isolated bacterial strain is stabilized in freeze dried, lyophilized or microencapsulated forms or wherein the non-viable cells is provided as a lysate, as a fraction, as a ferment, as metabolites, as an extract, as a derivative, as analogues, as postbiotics, as paraprobiotics or as a mutant of one of the bacterial strains.
22 . A composition comprising one or more isolated Lactobacillus crispatus (in particular, Lactobacillus crispatus LB714R, deposited under the accession number DSM 33732), one or more isolated Lactobacillus jensenii (in particular comprising Lactobacillus jensenii LB918R deposited under accession number DSM 34096), or one or more isolated Lactobacillus gasseri (in particular comprising Lactobacillus gasseri LB905R deposited under accession number DSM 34094) for the prevention, inhibition, or treatment of biofilm formation, wherein the isolated bacterial strain is stabilized in freeze dried, lyophilized or microencapsulated forms or wherein the non-viable cells is provided as a lysate, as a fraction, as a ferment, as metabolites, as an extract, as a derivative, as analogues, as postbiotics, as paraprobiotics or as a mutant of one of the bacterial strains.
23 . A composition comprising isolated Lactobacillus crispatus LB714R, deposited under the accession number DSM 33732 for use as a medicament, wherein the isolated bacterial strain is stabilized in freeze dried, lyophilized or microencapsulated forms or wherein the non-viable cells is provided as a lysate, as a fraction, as a ferment, as metabolites, as an extract, as a derivative, as analogues, as postbiotics, as paraprobiotics or as a mutant of one of the bacterial strains.
24 . A composition comprising isolated Lactobacillus crispatus LB714R, deposited under the accession number DSM 33732 for the prevention and/or treatment of a vaginal infection in a human or in an animal, wherein the isolated bacterial strain is stabilized in freeze dried, lyophilized or microencapsulated forms or wherein the non-viable cells is provided as a lysate, as a fraction, as a ferment, as metabolites, as an extract, as a derivative, as analogues, as postbiotics, as paraprobiotics or as a mutant of one of the bacterial strains.
25 . A composition comprising Lactobacillus crispatus LB714R, deposited under the accession number DSM 33732 for the improvement of fertility of a human or an animal and/or reducing the risk of premature birth of a human or an animal, wherein the isolated bacterial strain is stabilized in freeze dried, lyophilized or microencapsulated forms or wherein the non-viable cells is provided as a lysate, as a fraction, as a ferment, as metabolites, as an extract, as a derivative, as analogues, as postbiotics, as paraprobiotics or as a mutant of one of the bacterial strains.
26 . A medical device comprising the composition according to claim 13 , or a vaginal microbiome transplant according to claim 14 , or an isolated bacterial strain according to claim 17 .
27 . A method for selecting one or more lactic acid bacterial strains for vaginal transplantation comprising the step of selecting at least one first lactic acid bacterial strain characterized by inhibition of Gardnerella vaginalis and selecting at least one second strain characterized by inhibition of Candida albicans , wherein the inhibition of Gardnerella vaginalis and/or Candida albicans is provided by the inhibition or reduction in biofilm formation or the capability of preventing, inhibiting, or treating biofilm formation of pathogens, wherein the one or more lactic acid bacterial strains is stabilized in freeze dried, lyophilized or microencapsulated forms or wherein the non-viable cells is provided as a lysate, as a fraction, as a ferment, as metabolites, as an extract, as a derivative, as analogues, as postbiotics, as paraprobiotics or as a mutant of the one or more lactic acid bacterial strains.